Vera Therapeutics, Inc. $VERA Holdings Raised by Schroder Investment Management Group

Schroder Investment Management Group lifted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) by 82.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 679,992 shares of the company’s stock after acquiring an additional 307,243 shares during the period. Schroder Investment Management Group owned about 1.07% of Vera Therapeutics worth $19,652,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Virtus Investment Advisers LLC increased its stake in Vera Therapeutics by 14.8% during the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after purchasing an additional 539 shares during the last quarter. Invesco Ltd. lifted its position in shares of Vera Therapeutics by 2.0% in the 2nd quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock worth $656,000 after buying an additional 550 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of Vera Therapeutics by 13.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,254 shares of the company’s stock valued at $124,000 after buying an additional 615 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Vera Therapeutics by 2.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,721 shares of the company’s stock valued at $744,000 after buying an additional 816 shares during the period. Finally, Legal & General Group Plc boosted its holdings in shares of Vera Therapeutics by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock valued at $1,188,000 after buying an additional 825 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, SVP Joseph R. Young sold 3,117 shares of Vera Therapeutics stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $130,851.66. Following the sale, the senior vice president owned 64,722 shares of the company’s stock, valued at $2,717,029.56. The trade was a 4.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Sean Grant sold 4,949 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $207,759.02. Following the transaction, the chief financial officer owned 114,181 shares of the company’s stock, valued at $4,793,318.38. This trade represents a 4.15% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 33,490 shares of company stock valued at $1,405,910. 16.30% of the stock is currently owned by insiders.

Vera Therapeutics Trading Down 2.1%

Shares of NASDAQ:VERA opened at $41.17 on Friday. The company has a market cap of $2.88 billion, a PE ratio of -8.83 and a beta of 1.17. The company’s 50-day moving average price is $43.98 and its 200 day moving average price is $36.62. Vera Therapeutics, Inc. has a fifty-two week low of $18.53 and a fifty-two week high of $56.05. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.12.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Thursday, February 26th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same period in the previous year, the company posted ($0.72) EPS. Sell-side analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Evercore increased their price objective on shares of Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a research note on Wednesday, November 26th. JPMorgan Chase & Co. lowered their target price on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a report on Friday, December 19th. Pivotal Research set a $73.00 price target on Vera Therapeutics in a research report on Friday, December 5th. Finally, Bank of America raised their price target on Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $81.45.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.